Evidence map›Paper›PMID 33051280›Full record

ArticleBMJ open diabetes research & care2020

Incidence and regression of metabolic syndrome in a representative sample of the Spanish population: results of the cohort di@bet.es study.

Martín Cuesta, Manuel Fuentes, Miguel Rubio, Elena Bordiu, Ana Barabash, Nuria Garcia de la Torre, Gemma Rojo-Martinez, Sergio Valdes, Federico Soriguer, Joan Josep Vendrell and 16 more

Abstract read
In one paragraph

Article in BMJ open diabetes research & care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Martín Cuesta *Endocrinologia y Nutricion, Hospital Clínico San Carlos, Madrid, Spain.
Manuel Fuentes *Peventive Medicine Department, Hospital Clínico Universitario San Carlos, Madrid, Spain.
Miguel RubioEndocrinologia y Nutricion, Hospital Clínico San Carlos, Madrid, Spain.
Elena BordiuEndocrinologia y Nutricion, Hospital Clínico San Carlos, Madrid, Spain.
Ana BarabashEndocrinologia y Nutricion, Hospital Clínico San Carlos, Madrid, Spain.
Nuria Garcia de la TorreEndocrinologia y Nutricion, Hospital Clínico San Carlos, Madrid, Spain.
Gemma Rojo-MartinezEndocrinology and Nutrition Department, Hospital Universitario Carlos Haya, Malaga, Spain.
Sergio ValdesEndocrinology and Nutrition Department, Hospital Universitario Carlos Haya, Malaga, Spain.
Federico SoriguerEndocrinology and Nutrition Department, Hospital Universitario Carlos Haya, Malaga, Spain.
Joan Josep VendrellEndocrinology, University Hospital Joan XXIII, Tarragona, Spain.ORCID 0000-0002-6994-6115
Ines Maria UrrutiaEndocrinology and Diabetes Research Group,UPV/EHU, Endo-ERN (ID number 739527), BioCruces Health Research Institute, Barakaldo, Bizkaia, Spain.ORCID 0000-0001-5386-8776
Emilio OrtegaDepartment of Endocrinology and Nutrition, August Pi i Sunyer Biomedical Research Institute - IDIBAPS, Barcelona, Spain.
Eduard MontanyaHospital Universitario Bellvitge IDIBELL, Barcelona, Spain.
Eldelmiro MenendezDepartment of Endocrinology and Nutrition, Department of Medicine,University of Oviedo, Health Research Institute of the Principality of Asturias (ISPA), Central University Hospital of Asturias, Oviedo, Asturias, Spain.
Ana Lago-SampedroCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Malaga, Spain.
Ramón GomisDepartment of Endocrinology and Nutrition, August Pi i Sunyer Biomedical Research Institute - IDIBAPS, Barcelona, Spain.
Albert GodaySpanish Biomedical Research Network in Physiopathology of Obesity and Nutrition (CIBEROBN), Barcelona, Spain.
Conxa CastellDepartment of Health, Public Health Agency of Catalonia, Barcelona, Catalunya, Spain.
Rocio Badia-GuillenEndocrinology and Nutrition Department, Hospital Universitario Carlos Haya, Malaga, Spain.
Juan GirbésDiabetes Unit, Hospital Arnau de Vilanova, Valencia, Valenciana, Spain.
Sonia GaztambideSpanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Spanish Biomedical Research Network in Rare Diseases (CIBERER), Barakaldo, Spain.
Josep Franch-NadalCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barceloma, Spain.
Elías Delgado ÁlvarezSpanish Biomedical Research Network in Rare Diseases (CIBERER), Oviedo, Asturias, Spain.ORCID 0000-0001-6114-9712
Felipe Javier ChavesGenetic Diagnosis and Genotyping Unit, Fundacion Investigacion Clinico de Valencia-INCLIVA; CIBERDEM, Valencia, Valenciana, Spain.
Luis CastanoSpanish Biomedical Research Network in Diabetes and Associated Metabolic Disorders (CIBERDEM), Spanish Biomedical Research Network in Rare Diseases (CIBERER), Barakaldo, Spain.
Alfonso L Calle-PascualEndocrinologia y Nutricion, Hospital Clínico San Carlos, Madrid, Spain acalle.edu@gmail.com.ORCID 0000-0001-6114-9712

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMetabolic syndrome (MetS) is an important predictor of cardiovascular mortality. Identification of occurrence and regression trends of MetS could permit elaboration of preventive strategies with new targets. The objective of this study was to analyze the occurrence and regression rates of MetS and its associated factors in the representative cohort of Spain of the di@bet.es study. RESEARCH DESIGN AND

methodsThe di@bet.es study is a prospective cohort where 5072 people representative of the Spanish population over 18 years of age were randomly selected between 2009 and 2010. Follow-up was a median of 7.5 (IQR 7.2-7.9) years, with 2408 (47%) participating subjects. A total of 1881 (78%) subjects had all the pertinent data available and were included in this study.

resultsOf the 1146 subjects without baseline criteria for MetS, 294 (25.7%) developed MetS during follow-up, while of the 735 patients with prior MetS, 148 (20.1%) presented regression. Adjusted MetS incidence per 1000 person-years was 38 (95% CI 32 to 44), while regression incidence was 36 (95% CI 31 to 41). Regression rate was independently higher than incidence rate in the following: women, subjects aged 18-45, university-degree holders, patients without central obesity, without hypertension, as well as those with body mass index of <25 kg/m

conclusionsThis study provides MetS incidence and regression rates, and identifies the target population for intervention strategies in Spain and possibly in other countries.

Indexed as

Metabolic SyndromeAdolescentAdultCohort StudiesFemaleHumansIncidenceProspective StudiesSpainepidemiologylifestylemetabolic syndrome

Identifiers

PMID33051280
PMCPMC7554469

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.